FDA approves PTC’s ultra-rare disease gene therapy

The FDA has cleared PTC Therapeutics’ gene therapy for AADC deficiency, an ultra-rare disease that impacts the nerve cells and brain. The gene therapy was granted an expansive label encompassing children and adults across "the ...